Abstract
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with a disruption of all components of cancer care from screening, diagnosis, surveillance, treatment and clinical trial enrollment. Patients with cancer are considered a priority for SARS-CoV-2 vaccination. However, no data are available regarding patients with cancer enrolled in phase I trials and vaccination status.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
